Adaptive Shield Secures Strategic Investment from Blackstone
25.7.2023 16:30:00 EEST | Business Wire | Press release
Adaptive Shield, a leader in SaaS security, today announced a new investment from Blackstone Innovations Investments, Blackstone's strategic investment arm, bringing its total capital raised to $44M. This investment will be used to accelerate Adaptive Shield’s mission to protect companies as the number of SaaS applications used by enterprises has continued to grow rapidly. This growth is creating a new and complex mesh of business-critical applications that are increasingly being targeted by attackers.
“Thinking about where attackers are going next is key to growing a world-class cybersecurity program that protects our brand, reputation, investors, and intellectual property,” says Adam Fletcher, Chief Security Officer at Blackstone. “We have partnered with and are using Adaptive Shield to help us continuously monitor the security posture of business-critical SaaS applications used across Blackstone to further protect the firm from attackers. We believe in Adaptive Shield’s mission and are excited to support the company with our investment as they enter their next stage of growth.”
With Adaptive Shield, organizations can prevent, detect, and respond to identity-centric SaaS threats through Misconfiguration Management, SaaS-to-SaaS Access and Discovery, Identity & Access Governance, Device-to-SaaS User Risk Management, and Identity Threat Detection & Response (ITDR).
"Blackstone's investment demonstrates its success with our offering and underscores Adaptive Shield’s innovative capabilities as the only SaaS security platform to integrate with more than 130 applications that covers an expansive SaaS attack surface,” said Maor Bin, co-founder and CEO at Adaptive Shield. “With Blackstone's support, we will continue our trajectory for growth and expansion while keeping up with the constantly evolving threats.”
"At Blackstone, we have a dedicated team of cybersecurity professionals advising hundreds of our portfolio companies to further strengthen the cyber defense across the entire Blackstone ecosystem,” says Adam Mattina, Deputy Chief Security Officer and Head of Portfolio Cybersecurity at Blackstone. “We view the SaaS ecosystem as one of the top emerging attack vectors today, and our usage and investment in Adaptive Shield is highly strategic for the broader Blackstone portfolio as we collectively strive to stay ahead of such threats.”
To learn more about Adaptive Shield’s different use cases, please visit the use cases overview page.
About Adaptive Shield
Adaptive Shield, leader in SaaS Security, enables security teams to gain deep visibility and control over all business-critical SaaS applications and secure their entire SaaS stack through threat prevention, detection, and response. Founded by Maor Bin and Jony Shlomoff, Adaptive Shield works with many Fortune 500 enterprises and has been named Gartner® Cool VendorTM 2022. For more information, visit us at www.adaptive-shield.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230725843418/en/
Contact information
Media
Doug Fraim, Guyer Group
doug@guyergroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
